Predicted to enable enzyme binding activity and enzyme inhibitor activity. Predicted to contribute to GTPase activator activity. Predicted to be involved in several processes, including negative regulation of brown fat cell differentiation; negative regulation of nucleobase-containing compound metabolic process; and regulation of intracellular signal transduction. Predicted to act upstream of or within with a positive effect on negative regulation of cell population proliferation. Predicted to act upstream of or within negative regulation of epithelial cell proliferation and positive regulation of intrinsic apoptotic signaling pathway. Predicted to be located in several cellular components, including cell-cell contact zone; microtubule cytoskeleton; and midbody. Predicted to be part of FNIP-folliculin RagC/D GAP. Predicted to be active in cytosol. Used to study renal cell carcinoma. Human ortholog(s) of this gene implicated in Birt-Hogg-Dube syndrome; colorectal cancer; primary spontaneous pneumothorax; and renal cell carcinoma. Orthologous to human FLCN (folliculin); PARTICIPATES IN mTOR signaling pathway; renal cell carcinoma pathway; INTERACTS WITH 1-benzylpiperazine; 2,3,7,8-tetrachlorodibenzodioxine; 2,6-dinitrotoluene.
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FLCN mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FLCN mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FLCN mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FLCN mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FLCN mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of FLCN mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1 and 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FLCN mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLCN mRNA
[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLCN mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1 and 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FLCN mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1 and 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FLCN mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1 and 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FLCN mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1 and 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in increased expression of FLCN mRNA
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome.
in heterozygotes, a germline insertion of one nucleotide resulting in a nonsense mutation gives rise to renal adenocarcinomas by the age of 6 months; homozygosity is lethal at an early stage of embryogenesis
10 of 11 renal carcinomas showed a loss of heterozygosity at the Bhd locus and the one LOH-negative case displayed a spontaneous nonsense point mutation at the second Bhd locus